Role of estrogens in human benign prostatic hyperplasia

Archives of Andrology

Volumn 44, Issue 3, 2000, Pages 213-220

  Sciarra, Francesco ^a   Toscano, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiestrogens; Aromatase inhibitors; Benign prostatic hyperplasia (BPH); Estrogens; Phytoestrogens

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN; PHYTOESTROGEN; PLACEBO;

AGING; ANDROGEN METABOLISM; ARTICLE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ESTROGEN ACTIVITY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TESTOSTERONE BLOOD LEVEL;

EID: 79961155415     PISSN: 01485016     EISSN: None     Source Type: Journal    
DOI: 10.1080/014850100262191     Document Type: Article

References (56)

1. 1. Adlercreutz H, Hockerstedt K, Bannwart C, Bloigu S, Hamalainen E, Fotsis T, Ollus A (1987): Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin. J Steroid Biochem 27:1135-1144.
2. 2. Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hamalainen E, Hasegawa T, Okada H (1991): Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 54:1093-1100.
3. 3. Adlercreutz H, Markkanen H, Watanabe S (1993): Plasma concentrations of phytoestrogens in Japanese men. Lancet 342:1209-1210.
4. 4. Baker NWG, Burger HG, DeKretser DM, Hudson B, O'Connor S, Wang C, Mirovics A, Court J, Dunlop M, Rennie GC (1976): Changes in the pituitary-testicular system with age. Clin Endocrinol 5:349-357.
5. 5. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984): The development of human benign prostatic hyperplasia with age. J Urol 132:474-479.
6. 6. Bhatnagar AS, Hausler A, Trunet P, Schieweck K, Lang M, Bowman P (1990): Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 37:1021-1027.
7. 7. Brodie AMH, Wing LY, Goss P, Dowsett M, Coombes RC (1986): Aromatase inhibitors and their potential clinical significance. J Steroid Biochem 25:859-865.
8. 8. Brodie AMH (1994): Aromatase inhibitors in the treatment of breast cancer. J Steroid Biochem Mol Biol 49:281-287.
9. 9. Collins AT, Zhiming B, Gilmore K, Neal DE (1994): Androgen and oestrogen responsiveness of stromal cells derived from the human hyperplastic prostate: oestrogen regulation of the androgen receptors. J Endocrinol 143:269-277.
10. 10. Deslypere JP, Vermsulen A (1984): Leydig cell function in normal men: effect of age, life-style, residence, diet and activity. J Clin Endocrinol Metab 59:955-962.
11. 11. Di Silverio F, Tenaglia R (1986): Anti-estrogens and anti-androgens in human benign prostatic hyperplasia. In: Ipertrofia Prostatica Benigna. Di Silverio F, Neumann F, Tannenbaum M (Eds). Amsterdam: Excerpta Medica, pp 117-125.
12. 12. Ekman P, Barrack ER, Greene GL, Jensen EV, Walsh PC (1983): Estrogen receptors in human prostate: evidence for multiple binding sites. J Clin Endocrinol Metab 57:166-176.
13. 13. Ekman P (1989): BPH epidemiology and risk factors. Prostate, Suppl 2:23-31.
14. 14. El Etreby MF, Habenicht UF (1994): The function and the role of aromatase inhibitors in the treatment of BPH. In: Benign Prostatic Hyperplasia. Kurt K, Newling DWW (Eds). New York: Wiley-Liss, pp 209-230.
15. 15. Geelen JAA, Loozen HJJ, Deckers GH, de Leeuw R, Kloosterboer HJ, Lamberts SWJ (1993): ORG 33201: a new highly selective orally active aromatase inhibitor. J Steroid Biochem Mol Biol 44:4-6.
16. 16. Geller J, Albert JD (1985): BPH and prostate cancer: results of hormonal manipulation. In: Regulation of Androgen Action. Bruchovsky N, Chapdelaine A, Neumann F (Eds). Berlin: Congressdruck R. Bruchner, pp 51-75.
17. 17. Gingell JC, Knonagel H, Kurth KH, Tunn UW (1995): Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group. J Urol 154:399-401.
18. 18. Graham S, Haughey B, Marshall J (1983): Diet in the epidemiology of carcinoma of the prostate gland. JNCI 70:687-692.
19. 19. Griffiths K, Coffey D, Cockett A, Ichikawa T, Lee C, Schalken J, Steiner G, Yamanaka H, di Sant'Agnese A, Krieg M, McKeehan W, Sciarra F, Sugimura Y (1995): The regulation of prostatic growth. 3rd Intern. Consultation on BPH, Principato di Monaco, S.C.I. Paris, pp 73-115.
20. 20. Griffiths K, Adlercreutz H, Boyle P, Denis L, Nicholson RI, Morton MS (1996): Nutrition and Cancer. Oxford, UK: Isis Medical Media, pp 1-16.
21. 21. Hahn EF, Fishman J (1984): Immunological probe for estrogen biosynthesis: evidence for the 2β-hydroxylative pathway in aromatization of androgens. J Biol Chem 259:1689-1694.
22. 22. Haugen OA, Harbitz TB (1972): Prostatic weight in elderly men: an analysis in an autopsy series. Acta Pathol Microbiol Scand [A] 80:756-767.
23. 23. Henderson D, Habenicht UF, Nishino Y, Kerb U, El Etreby MF (1986): Aromatase inhibitors and benign prostatic hyperplasia. J Steroid Biochem 25:867-876.
24. 24. Henderson D, Habenicht UF, Nishino Y, El Etreby MF (1987): Estrogens and benign prostatic hyperplasia: the basis of aromatase inhibitor therapy. Steroids 50:219-233.
25. 25. Horton R (1984): Benign prostatic hyperplasia a disorder of androgen metabolism in the male. Am J Geriatr 32:380-390.
26. 26. Khan CR, Smith RJ, Chin WW (1998): Mechanism of action of hormones that act at the cell surphace. In: Williams Textbook of Endocrinology. Wilson JD, Foster DW (Eds). Philadelphia: Saunders, pp 95-134.
27. 27. Korach KS (1994): Insights from the study of animals lacking functional estrogen receptor. Science 266:1524-1527.
28. 28. Krieg M, Klotzl G, Kaufmann J, Voigt KD (1981): Stroma human benign prostatic hyperplasia: preferential tissue for androgen metabolism and estrogen binding. Acta Endocrinol (Copenh) 96:422-432.
29. 29. Krieg M, Bartsch W, Thomsen M, Voight KD (1982): Androgens and estrogens: their interaction with stroma and epithelium of human prostatic hyperplasia and normal prostate. J Steroid Biochem 5:155-161.
30. 30. Krieg M, Nass R, Tunn S (1993): Effect of aging on endogenous levels of 5α-dihydrotestosterone, testosterone, estradiol and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Endocrinol 77:375-381.
31. 31. Kurzer MS, Xu X (1997): Dietary phytoestrogens. Annu Re Nutr 17:353-358.
32. 32. Lipton A, Harvey HA, Demers LM, Hanagan JR, Mulaga M, Kochak GM, Fitzsimmons S, Snaders SI, Santen RJ (1990): A phase I trial of CGS 16949A: a new aromatase inhibitor. Cancer 65:1279-1286.
33. 33. Lubrano C, Sciarra F, Spera G, Petrangeli E, Toscano V, Rombolà N, Palleschi F, Palma E, Di Silverio F (1992): Immunoreactive EGF in human benign prostatic hyperplasia: relationships with androgen and estrogen receptors. J Steroid Biochem Mol Biol 41:683-687.
34. 34. Mettlin C, Selenskas S, Natarajan N, Huben R (1986): Beta-carotene and animal fats and their relationship to prostate cancer risk: a case control study. Cancer 53:817-821.
35. 35. Mills PK, Beeson WL, Phillips RL, Fraser GE (1989): Cohort study lifestyle and prostate cancer in Adventist men. Cancer 64:598-604.
36. 36. Mont S, Di Silverio F, Toscano V, Martini C, Lanzara S, Varasano PA, Sciarra F(1998): Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH). J Androl 19:428-433.
37. 37. Nicholson RI, Davies P, Griffiths K (1978): Interaction of androgens with estradiol-17β receptor proteins in DMBA-induced mammary tumours: a possible oncolytic mechanism. Eur J Cancer 14:439-445.
38. 38. Radlmaier A, Eickenberg HU, Fletcher MS, Fourcade RO, Reis Santos JM, van Aubel OG, Bono AV (1996): Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Prostate 29:199-208.
39. 39. Schneider G, Kirschner MA, Ertel NH (1977): Increased serum estradiol in morbidly obese males. Endocrinology [Suppl 1], 100:211-215.
40. 40. Schweikert HU, Tunn UW, Habenicht UF, Arnold J, Senge T, Schulze H, Schroder FH, Blom JH, Ennemoser O, Horniger W (1993): Effects of estrogen deprivation on human benign prostatic hyperplasia. J Steroid Biochem Mole Biol 44:573-576.
41. 41. Sciarra F, Concolino G, Tenaglia R, Di Silverio F (1988): Biochemical modifications in human benign prostatic hyperplasia (BPH). In: New Trends in BPH Etiopathogenesis, Di Silverio F, Steg A (Eds). Rome: Acta Medica, pp 277-282.
42. 42. Sciarra F (1991): Fattori ormonali nella etiopatogenesi dell'ipertrofia prostatica benigna. In: Ghiandole Endocrine e Invecchiamento, Andreani D, Motta M (Eds). Rome: Tipografia Poliglotta Vaticana, pp 195-206.
43. 43. Sciarra F (1995): Sex steroids and epidermal growth factor in benign prostatic hyperplasia. In: Steroid Receptors and Antihormones. Annals New York Acad Sci 761:66-78.
44. 44. Sciarra F, Monti S, Trotta MC, Martini C, Tosti-Croce C, Toscano V (1995): Sistema riproduttivo maschile e invecchiamento. In: Atti VIII Convegno Internazionale di Endocrinologia Medico-Chirurgica, Zarrilli L (Ed). Isola di Procida, pp 15-30.
45. 45. Severson RK, Nomura AMY, Grove JS, Stemmerman GN (1989): A prospective study of demographics and prostate cancer among Japanese ancestry in Hawaii. Cancer Res 49:1857-1860.
46. 46. Snowdon DA, Philips RL, Choi W (1984): Diet, obesity and risk of fatal prostate cancer. Am J Epidemiol 120:244-250.
47. 47. Talamini R, La Vecchia C, Decarli A (1986): Nutrition, social factors and prostatic cancer in a Northern Italian population. Br J Cancer 53:817-821.
48. 48. Trunet PF, Mueller Ph, Bhatnagar AS, Dickes I, Monnet G, White G (1993): Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20267, in healthy male subjects. J Clin Endocrinol Metab 77:319-323.
49. 49. Tunn UW, Kaivers P, Schweikert HU (1985): Conservative treatment of human benign prostatic hyperplasia. In: Regulation of Androgen Action, Bruchovsky N, Chapdelaine A, Neumann F (Eds). Berlin: Congressdruck R. Bruckner, pp 87-90.
50. 50. Tunn UW, Schweikert HU (1989): Aromatase inhibitors in the management of benign prostatic hyperplasia. In: New Developments in Biosciences 5. Berlin: de Gruyter, pp 139-149.
51. 51. Vermeulen A, Rubens R, Verdonck L (1972): Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab 34:730-739.
52. 52. Vermeulen A, De Sy (1976): Androgens in patients with benign prostatic hyperplasia before and after prostatectomy. J Clin Endocrinol Metab 43:1250-1254.
53. 53. Voigt KD, Bartsch W (1986): Intratissular androgens in benign prostatic hyperplasia and prostate cancer. J Steroid Biochem 25:749-757.
54. 54. Von Schoultz B, Carlstrom K (1989): On the regulation of sex-hormone binding globulin: a challenge of an old dogma and outlines of an alternative mechanism. J Steroid Biochem 32:327-334.
55. 55. Walsh PC, Hutchins GM, Ewing LL (1983): Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal. J Clin Invest 72:1772-1781.
56. 56. Yatani R, Chigusa I, Akazaki K, Stemmerman GN, Welsh RA, Correa P (1982): Geographic pathology of latent prostatic cancer. Int J Cancer 29:611-616.